Single-Molecule Detection for Endometriosis Diagnosis

Endometriosis affects about 1 in 10 women of reproductive age, yet diagnosis often takes 7–10 years and typically relies on invasive laparoscopy. There is an urgent need for non-invasive, reliable tests that can detect the disease earlier.

This is where single-molecule detection technology comes in. Unlike traditional immunoassays, Single molecule arrays (SIMOA) can detect biomarkers at femtomolar concentrations, enabling the identification of biomarkers that are otherwise undetectable. For endometriosis, this means the possibility of discovering and validating molecular signatures in blood or urine rather than through surgery.

Currently, we are using SIMOA to explore biomarker discovery for endometriosis. The goal is to develop a diagnostic approach that is not only more sensitive but also less invasive, ultimately improving how we identify and treat this complex condition.

With continued progress, SIMOA-driven biomarker discovery could transform endometriosis diagnosis from years of uncertainty to a simple test with timely answers.

Endometriosis